David R. Nelson
- Hepatology top 0.02%
- Hepatitis C virus research 171
- Liver Disease and Transplantation 37
- Epidemiology top 0.05%
- Liver Disease Diagnosis and Treatment 112
- Hepatitis B Virus Studies 73
- Transplantation top 0.5%
- Infectious Diseases top 0.5%
- HIV/AIDS drug development and treatment 29
- Rheumatology top 1%
- Systemic Lupus Erythematosus Research 29
-
- Chronic Lymphocytic Leukemia Research 15
-
- Immune Cell Function and Interaction 13
David R. Nelson
259 papers receiving 13.6k citations
Hit Papers
Peers
Comparison fields: 5 of 170
- Hepatology 10.4k
- Epidemiology 9.0k
- Transplantation 436
- Infectious Diseases 1.7k
- Rheumatology 950
Countries citing papers authored by David R. Nelson
This map shows the geographic impact of David R. Nelson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David R. Nelson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David R. Nelson more than expected).
Fields of papers citing papers by David R. Nelson
This network shows the impact of papers produced by David R. Nelson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David R. Nelson. The network helps show where David R. Nelson may publish in the future.
Co-authorship network
The 25 scholars most cited alongside David R. Nelson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 4 | |
| 3 | 2019 | 34 | |
| 4 | Evaluating Podcast Compositions: Assessing Credibility, Challenges, and Innovation | 2016 | 7 |
| 5 | 2016 | 61 | |
| 6 | Open-Label Study to Evaluate the Safety & Tolerability of Telaprevir in Combination with Sofosbuvir in Naive Subjects with HCV Genotype 1 Short Title: Telaprevir & Sofosbuvir in HCV Genotype 1 | 2015 | 2 |
| 7 | 2015 | 1 | |
| 8 | ABT-450/r/Ombitasvir plus Dasabuvir With or Without Ribavirin in HCV Genotype 1-infected Patients with History of Depression or Bipolar Disorder: Pooled Analysis of Efficacy and Safety in Phase 3 Trials | 2014 | 5 |
| 9 | HCVerso2: a phase III study of faldaprevir plus deleobuvir and ribavirin for chronic HCV genotype 1b infection in treatment naïve patients including those ineligible for pegylated interferon | 2014 | 1 |
| 10 | 2011 | 1 | |
| 11 | Cooperative Adaptive Cruise Control: Testing Drivers' Choices of Following Distances | 2011 | 51 |
| 12 | Generating Digital Terrain Models from LROC stereo images with Socet Set | 2010 | 15 |
| 13 | 2009 | 198 | |
| 14 | 2008 | 11 | |
| 15 | 2007 | 4 | |
| 16 | Modulation of interferon-specific gene expression by albumin-interferon-alpha in interferon-alpha-experienced patients with chronic hepatitis C. | 2006 | 12 |
| 17 | Demonstration of Automated Heavy-Duty Vehicles | 2006 | 7 |
| 18 | 2005 | 43 | |
| 19 | 2005 | 29 | |
| 20 | 1986 | 31 |
About David R. Nelson
David R. Nelson is a scholar working on Hepatology, Epidemiology and Rheumatology, having authored 266 papers that have together received 14.0k indexed citations. Recurring topics across this work include Hepatitis C virus research (171 papers), Liver Disease Diagnosis and Treatment (112 papers), Hepatitis B Virus Studies (73 papers), Liver Disease and Transplantation (37 papers), Systemic Lupus Erythematosus Research (29 papers), HIV/AIDS drug development and treatment (29 papers), Chronic Lymphocytic Leukemia Research (15 papers) and Immune Cell Function and Interaction (13 papers). The work is most often cited by research in Hepatology (10.4k citations), Epidemiology (9.0k citations) and Transplantation (436 citations). David R. Nelson has collaborated with scholars based in United States, Germany and France. Frequent co-authors include Roniel Cabrera, Chen Liu, Roberto J. Firpi, Michael Fried, Gary L. Davis, Mark Sulkowski, Doris B. Strader, Marc G. Ghany, Leonard B. Seeff and David L. Thomas. Their work appears in journals such as New England Journal of Medicine, The Lancet and Physical Review Letters.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.